Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus FOLFIRI in 2nd-line MSS/pMMR mCRC
NCT07021950Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07021950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021950.